PAA
PACB icon

Peregrine Asset Advisers’s Pacific Biosciences PACB Stock Holding History

Peregrine Asset Advisers’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-42,750
Closed -$264K – 132
2014
Q2 		$264K Buy
+42,750
New +$214K 0.24% 84

Other funds holding PACB

MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RCM
Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Peregrine Asset Advisers's PACB Position: Q3 2014 in Review

Peregrine Asset Advisers sold out of Pacific Biosciences (PACB) in Q3 2014, closing a stake of 42,750 shares — an estimated $264K sold.

Peregrine Asset Advisers first reported a position in PACB in Q2 2014 and held it in 1 quarter. The position peaked at $264K in Q2 2014. 88 funds tracked by Wall St. Rank hold PACB as of Q3 2014.

  • Peregrine Asset Advisers reported no remaining Pacific Biosciences position as of Q3 2014 after selling out during the quarter.
  • Peregrine Asset Advisers sold 42,750 Pacific Biosciences shares in Q3 2014, an estimated $264K.
  • Peregrine Asset Advisers first reported a position in Pacific Biosciences in Q2 2014 and held it in 1 quarter.
  • Peregrine Asset Advisers's Pacific Biosciences position peaked at $264K in Q2 2014.
  • 88 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2014.

Based on Peregrine Asset Advisers's 13F filing for Q3 2014, filed 13 Nov 2014.